We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Cabot (CBT) Down 10.9% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Cabot (CBT - Free Report) . Shares have lost about 10.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Cabot due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Cabot's Earnings and Revenues Trail Estimates in Q1
Cabot reported profits of $41 million or 70 cents per share in the first quarter of fiscal 2019 (ended Dec 31, 2019), down from $69 million or $1.14 per share in the year-ago quarter.
Barring one-time items, adjusted earnings per share were 69 cents, down from 87 cents in the year-ago quarter. Also, the figure missed the Zacks Consensus Estimate of 76 cents.
Net sales fell 11.4% year over year to $727 million in the quarter. It also trailed the Zacks Consensus Estimate of $793.6 million.
Segment Highlights
Reinforcement Materials’ sales fell 17.1% year over year to $379 million in the reported quarter. Earnings before Interest and Tax (EBIT) in the segment were $47 million, down 24.2% year over year. Margins were affected by lower volumes globally, which also led to lower energy center revenues and a slower inventory turnover.
Sales in the Performance Chemicals unit went up 4.8% year over year to $242 million in the reported quarter. EBIT rose 13.9% year over year to $41 million on higher volume.
Sales in the Purification Solutions declined 9.2% year over year to $59 million in the quarter. The segment generated a loss of $2 million, which was narrower than a loss of $3 million in the year-ago quarter.
Financial Position
Cabot had cash and cash equivalents of $173 million at the end of fiscal first quarter, up 21.8% year over year. The company’s long-term debt rose 73.5% year over year to $1,095 million.
Cash flows from operating activities were $105 million in the reported quarter. Capital expenditures were $68 million.
Outlook
For the Reinforcement Materials unit, the company expects to benefit from the calendar year 2020 customer agreements. Moreover, volumes are likely to return to a normalized level starting second-quarter fiscal 2020.
In the Performance Chemicals unit, the company anticipates the challenging price environment for fumed silica in Europe and China that it witnessed during the fiscal first quarter. The trend is likely to continue in the near-term.
For the Purification Solutions unit, the company continues to expect improvement in EBIT on a year-over-year basis.
For fiscal 2020, adjusted earnings are projected in the range of $3.60-$3.90 per share compared with $3.60-$4.10 expected earlier.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -16.88% due to these changes.
VGM Scores
At this time, Cabot has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Cabot has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Cabot (CBT) Down 10.9% Since Last Earnings Report?
It has been about a month since the last earnings report for Cabot (CBT - Free Report) . Shares have lost about 10.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Cabot due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Cabot's Earnings and Revenues Trail Estimates in Q1
Cabot reported profits of $41 million or 70 cents per share in the first quarter of fiscal 2019 (ended Dec 31, 2019), down from $69 million or $1.14 per share in the year-ago quarter.
Barring one-time items, adjusted earnings per share were 69 cents, down from 87 cents in the year-ago quarter. Also, the figure missed the Zacks Consensus Estimate of 76 cents.
Net sales fell 11.4% year over year to $727 million in the quarter. It also trailed the Zacks Consensus Estimate of $793.6 million.
Segment Highlights
Reinforcement Materials’ sales fell 17.1% year over year to $379 million in the reported quarter. Earnings before Interest and Tax (EBIT) in the segment were $47 million, down 24.2% year over year. Margins were affected by lower volumes globally, which also led to lower energy center revenues and a slower inventory turnover.
Sales in the Performance Chemicals unit went up 4.8% year over year to $242 million in the reported quarter. EBIT rose 13.9% year over year to $41 million on higher volume.
Sales in the Purification Solutions declined 9.2% year over year to $59 million in the quarter. The segment generated a loss of $2 million, which was narrower than a loss of $3 million in the year-ago quarter.
Financial Position
Cabot had cash and cash equivalents of $173 million at the end of fiscal first quarter, up 21.8% year over year. The company’s long-term debt rose 73.5% year over year to $1,095 million.
Cash flows from operating activities were $105 million in the reported quarter. Capital expenditures were $68 million.
Outlook
For the Reinforcement Materials unit, the company expects to benefit from the calendar year 2020 customer agreements. Moreover, volumes are likely to return to a normalized level starting second-quarter fiscal 2020.
In the Performance Chemicals unit, the company anticipates the challenging price environment for fumed silica in Europe and China that it witnessed during the fiscal first quarter. The trend is likely to continue in the near-term.
For the Purification Solutions unit, the company continues to expect improvement in EBIT on a year-over-year basis.
For fiscal 2020, adjusted earnings are projected in the range of $3.60-$3.90 per share compared with $3.60-$4.10 expected earlier.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -16.88% due to these changes.
VGM Scores
At this time, Cabot has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Cabot has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.